CSI Market
Sign In | Register

Lyell Immunopharma Inc (LYEL) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LYEL Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Lyell Immunopharma Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-68.91
Depreciation & amortization4.55
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property-0.12
Share-based Compensation8.83
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Fair Value Adjustment Of Success Payment Liabilities-0.35
Impairment Of Investments-
Sale And Leaseback Transaction Gain Loss Net-
Gain Loss On Remeasurement Of Convertible Preferred Stock Tranche Liabilities-
Expense In Connection With Equity Issuances-
Gain Loss On Termination Of Lease-
Increase Decrease In Contract With Customer Liability-
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Equity Securities Fv Ni Unrealized Loss-
Asset Acquisition Contingent Consideration Arrangements Change In Fair Value-
Non Cash Lease Income Expense-1.10
Income taxes0.00
Gain (Loss) on Sale of Other Investments0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.92
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities1.04
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-3.33
Other Working Capital0.02
Other Noncash Income (Expense)0.00
Other net1.71
Payments for (Proceeds from) Other Operating Activities-17.15
Discontinued operations0.00
Net Cash flow from Operating Activities-72.43
Investing Activities
Capital Expenditures-0.35
Sale of Capital Items0.01
Proceeds from Sale and Maturity of Available-for-sale Securities124.04
Payments to Acquire Available-for-sale Securities, Debt-90.71
Real Estate Investments0.00
Payments For Asset Acquisitions Net Of Cash Acquired-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities32.99
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.55
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net51.70
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents61.77
Payment Proceeds Tax Withholding Share Based Payment Arrangement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities52.24
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-72.77
Total Cash Flow12.81
4 historic quarters locked

Sign in to unlock the full Lyell Immunopharma Inc cash flow history.

Sign In Create Free Account

About Lyell Immunopharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-054367

Figures are derived from filed reports and may be restated. Historical data is subject to revision.